Ethambutol 400 Mg Pharma-Q 400 mg FC tablets
PDF Leaflet Revision Date: 13 May 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of tuberculosis with other anti-tuberculosis medicines.
Dosage (summary)
15 mg/kg daily for primary treatment; 25 mg/kg for first 60 days of re-treatment, then 15 mg/kg.
Special Populations
- Renal impairment
- Elderly
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established; breastfeeding not recommended during treatment.
Key Drug Interactions
- Aluminium hydroxide reduces absorption
Contraindications
- Hypersensitivity to ethambutol
- Severe renal impairment
- Optic neuritis
Common side effects
- Optic neuritis
- Hyperuricaemia
- Peripheral neuropathy
- Nausea
- Dizziness
Counselling Points
- Report any vision changes
- Avoid driving if vision impaired
- Regular ophthalmic examinations for high-risk patients
Serious warnings
- Risk of optic neuritis
- Monitor renal function
- Visual acuity tests recommended
Important Disclaimer
The Ethambutol 400 Mg Pharma-Q 400 mg FC tablets professional information leaflet below is the property of Pharma-Q and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
